Search

Your search keyword '"Iborra Colomino M"' showing total 11 results
Start Over Author "Iborra Colomino M"
11 results on '"Iborra Colomino M"'

1. P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry

Author

Iborra Colomino, M I, primary, Garrido Marín, A, additional, Caballol Oliva, B, additional, Huguet Malavés, J M, additional, Arias García, L, additional, Mesonero Gismero, F, additional, Fernández Prada, S J, additional, Boscá Watts, M M, additional, Ponferrada Díaz, Á, additional, Calvet Calvo, X, additional, Gutiérrez Casbas, A, additional, Ordás Jiménez, I, additional, Ruiz Sanchez, L, additional, Sicilia Aladren, B, additional, Garcia de la Filia, I, additional, Domènech Morral, E, additional, and Nos Mateu, P, additional

Published
2023
Full Text
View/download PDF

2. P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients

Author

Iborra Colomino, M I, primary, Ferreiro-Iglesias, R, additional, Martín-Arranz, M D, additional, Mesonero-Gismero, F, additional, Mínguez, A, additional, Porto Silva, S, additional, García-Ramírez, L, additional, García de la Filia, I, additional, Bastida, G, additional, Nieto García, L, additional, Suárez Ferrer, C, additional, Aguas, M, additional, Barreiro de Acosta, M, additional, and Nos, P, additional

Published
2023
Full Text
View/download PDF

3. P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry

Author

Casas Deza, D, primary, Lamuela Calvo, L J, additional, Arbonés Mainar, J M, additional, Ricart, E, additional, Gisbert, J P, additional, Rivero Tirado, M, additional, Sanchez Rodríguez, E, additional, Sicilia, B, additional, Gutierrez Casbas, A, additional, Merino Ochoa, O, additional, Márquez, L, additional, Laredo de la Torre, V, additional, Martin Arranz, M D, additional, Lopez Serrano, P, additional, Riestra Menéndez, S, additional, Gonzalez Muñoza, C, additional, de Castro Parga, L, additional, Calvo Moya, M, additional, Garcia Alonso, J, additional, Esteve, M, additional, Iborra Colomino, M, additional, Dura Gil, M, additional, Barreiro de Acosta, M, additional, Lorente Poyatos, R, additional, Manceñido, N, additional, Caballo, B, additional, Calafat, M, additional, Rodríguez Lago, I, additional, Guardiola Capo, J, additional, Morales Alvarado, V J, additional, Tardillo, C, additional, Bujanda, L, additional, Muñoz Nuñez, J F, additional, Ber Nieto, Y, additional, Bermejo, F, additional, Chaparro, M, additional, Almela, P, additional, Navarro, M, additional, Domènech, E, additional, and García López, S, additional

Published
2021
Full Text
View/download PDF

4. P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry

Author

Iborra Colomino, M I, primary, Beltrán, B, additional, Fernández-Clotet, A, additional, Iglesias Flores, E, additional, Navarro, P, additional, Rivero, M, additional, Gutiérrez, A, additional, Sierra-Ausin, M, additional, Mesonero, F, additional, Ferreiro-Iglesias, R, additional, Hinojosa, J, additional, Calvet, X, additional, Sicilia, B, additional, González-Muñoza, C, additional, Antolín, B, additional, González Vivo, M, additional, Carbajo, A Y, additional, García, S, additional, Martín-Cardona, A, additional, Surís Marín, G, additional, Martín-Arranz, M D, additional, De Francisco, R, additional, Cañete, F, additional, Carlos, T, additional, Gomollón, F, additional, Lorente, R, additional, Rodríguez-Lago, I, additional, Forés-Bosch, A, additional, Bernardos, E, additional, Ramos, L, additional, Delgado, P, additional, Hernández, A, additional, Van Domselaar, M, additional, Hervás, D, additional, Domènech, E, additional, and Nos, P, additional

Published
2020
Full Text
View/download PDF

5. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Author

Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional

Published
2019
Full Text
View/download PDF

8. Development of hepatocellular carcinoma (HCC) in peginterferon and ribavirin HCV-infected cirrhotic treated patients

Author

Berenguer Haym M, Iborra Colomino M, and Aguilera Sancho-Tell

Subjects
medicine.medical_specialty, Carcinoma, Hepatocellular, Hepacivirus, Alpha interferon, Interferon alpha-2, Antiviral Agents, Gastroenterology, law.invention, chemistry.chemical_compound, Text mining, Liver Function Tests, law, Internal medicine, Ribavirin, Humans, Medicine, biology, medicine.diagnostic_test, business.industry, Interferon-alpha, General Medicine, Hepatitis C, Chronic, Viral Load, biology.organism_classification, medicine.disease, Recombinant Proteins, Treatment Outcome, chemistry, Hepatocellular carcinoma, Recombinant DNA, business, Liver function tests, Viral load
Published
2006
Full Text
View/download PDF

11. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.

Author

Rodríguez-Moranta F, Argüelles-Arias F, Hinojosa Del Val J, Iborra Colomino M, Martín-Arranz MD, Menchén Viso L, Muñoz Núñez F, Ricart Gómez E, Sánchez-Hernández JG, Valdés-Delgado T, Guardiola Capón J, Barreiro-de Acosta M, Mañosa Ciria M, Zabana Abdo Y, and Gutiérrez Casbas A

Subjects
Humans, Inflammatory Bowel Diseases drug therapy, Drug Monitoring, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Biological Products therapeutic use, Biological Products pharmacokinetics
Abstract

The treatment of inflammatory bowel disease has undergone a significant transformation following the introduction of biologic drugs. Thanks to these drugs, treatment goals have evolved from clinical response and remission to more ambitious objectives, such as endoscopic or radiologic remission. However, even though biologics are highly effective, a significant percentage of patients will not achieve an initial response or may lose it over time. We know that there is a direct relationship between the trough concentrations of the biologic and its therapeutic efficacy, with more demanding therapeutic goals requiring higher drug levels, and inadequate exposure being common. Therapeutic drug monitoring of biologic medications, along with pharmacokinetic models, provides us with the possibility of offering a personalized approach to treatment for patients with IBD. Over the past few years, relevant information has accumulated regarding its utility during or after induction, as well as in the maintenance of biologic treatment, in reactive or proactive strategies, and prior to withdrawal or treatment de-escalation. The aim of this document is to establish recommendations regarding the utility of therapeutic drug monitoring of biologics in patients with inflammatory bowel disease, in different clinical practice scenarios, and to identify areas where its utility is evident, promising, or controversial., (Copyright © 2024 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results